Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.

Harel ET, Drake PM, Barfield RM, Lui I, Farr-Jones S, Van't Veer L, Gartner ZJ, Green EM, Lourenço AL, Cheng Y, Hann BC, Rabuka D, Craik CS.

Antibodies (Basel). 2019 Nov 5;8(4). pii: E54. doi: 10.3390/antib8040054.

2.

Pharmacokinetics of Human Recombinant Anti-Botulinum Toxin Antibodies in Rats.

Espinoza Y, Wong D, Ahene A, Der K, Martinez Z, Pham J, Cobb RR, Farr-Jones S, Marks JD, Tomic MT.

Toxins (Basel). 2019 Jun 17;11(6). pii: E345. doi: 10.3390/toxins11060345.

3.

Monoclonal Antibody Combinations Prevent Serotype A and Serotype B Inhalational Botulism in a Guinea Pig Model.

Tomic MT, Espinoza Y, Martinez Z, Pham K, Cobb RR, Snow DM, Earnhart CG, Pals T, Syar ES, Niemuth N, Kobs DJ, Farr-Jones S, Marks JD.

Toxins (Basel). 2019 Apr 6;11(4). pii: E208. doi: 10.3390/toxins11040208.

4.

An ambient temperature-stable antitoxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E.

Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT.

PLoS One. 2018 May 10;13(5):e0197011. doi: 10.1371/journal.pone.0197011. eCollection 2018.

5.

Antibody engineering to improve manufacturability.

Wijesuriya SD, Pongo E, Tomic M, Zhang F, Garcia-Rodriquez C, Conrad F, Farr-Jones S, Marks JD, Horwitz AH.

Protein Expr Purif. 2018 Sep;149:75-83. doi: 10.1016/j.pep.2018.04.003. Epub 2018 Apr 12.

PMID:
29655788
6.

A Three Monoclonal Antibody Combination Potently Neutralizes Multiple Botulinum Neurotoxin Serotype E Subtypes.

Garcia-Rodriguez C, Razai A, Geren IN, Lou J, Conrad F, Wen WH, Farr-Jones S, Smith TJ, Brown JL, Skerry JC, Smith LA, Marks JD.

Toxins (Basel). 2018 Mar 1;10(3). pii: E105. doi: 10.3390/toxins10030105.

7.

A Single Tri-Epitopic Antibody Virtually Recapitulates the Potency of a Combination of Three Monoclonal Antibodies in Neutralization of Botulinum Neurotoxin Serotype A.

Lou J, Wen W, Conrad F, Meng Q, Dong J, Sun Z, Garcia-Rodriguez C, Farr-Jones S, Cheng LW, Henderson TD, Brown JL, Smith TJ, Smith LA, Cormier A, Marks JD.

Toxins (Basel). 2018 Feb 15;10(2). pii: E84. doi: 10.3390/toxins10020084.

8.

Discovery of internalizing antibodies to basal breast cancer cells.

Zhou Y, Zou H, Yau C, Zhao L, Hall SC, Drummond DC, Farr-Jones S, Park JW, Benz CC, Marks JD.

Protein Eng Des Sel. 2018 Jan 1;31(1):17-28. doi: 10.1093/protein/gzx063.

9.

High-throughput screening: update on practices and success.

Fox S, Farr-Jones S, Sopchak L, Boggs A, Nicely HW, Khoury R, Biros M.

J Biomol Screen. 2006 Oct;11(7):864-9. Epub 2006 Sep 14.

PMID:
16973922
10.

Chemokine antagonists as anti-inflammatory and antiviral agents II.

Farr-Jones S.

IDrugs. 2000 Jun;3(6):584-5. No abstract available.

PMID:
16096911
11.
12.

High-throughput screening: searching for higher productivity.

Fox S, Farr-Jones S, Sopchak L, Boggs A, Comley J.

J Biomol Screen. 2004 Jun;9(4):354-8. No abstract available.

PMID:
15191652
13.

High throughput screening 2002: moving toward increased success rates.

Fox S, Wang H, Sopchak L, Farr-Jones S.

J Biomol Screen. 2002 Aug;7(4):313-6. No abstract available.

PMID:
12230884
14.

The Internet for nuclear magnetic resonance spectroscopists.

Avizonis D, Farr-Jones S.

Methods Enzymol. 2001;338:247-57. No abstract available.

PMID:
11460551
15.

High Throughput Screening for Drug Discovery: Continually Transitioning into New Technology.

Fox S, Farr-Jones S, Yund MA.

J Biomol Screen. 1999;4(4):183-186.

PMID:
10838437
16.

Solution structure of Syrian hamster prion protein rPrP(90-231).

Liu H, Farr-Jones S, Ulyanov NB, Llinas M, Marqusee S, Groth D, Cohen FE, Prusiner SB, James TL.

Biochemistry. 1999 Apr 27;38(17):5362-77.

PMID:
10220323
17.

NMR determination of the major solution conformation of a peptoid pentamer with chiral side chains.

Armand P, Kirshenbaum K, Goldsmith RA, Farr-Jones S, Barron AE, Truong KT, Dill KA, Mierke DF, Cohen FE, Zuckermann RN, Bradley EK.

Proc Natl Acad Sci U S A. 1998 Apr 14;95(8):4309-14.

18.

Solution structure of a 142-residue recombinant prion protein corresponding to the infectious fragment of the scrapie isoform.

James TL, Liu H, Ulyanov NB, Farr-Jones S, Zhang H, Donne DG, Kaneko K, Groth D, Mehlhorn I, Prusiner SB, Cohen FE.

Proc Natl Acad Sci U S A. 1997 Sep 16;94(19):10086-91.

19.
20.

Converting trypsin to chymotrypsin: ground-state binding does not determine substrate specificity.

Hedstrom L, Farr-Jones S, Kettner CA, Rutter WJ.

Biochemistry. 1994 Jul 26;33(29):8764-9.

PMID:
8038166
21.

Crystal versus solution structure of enzymes: NMR spectroscopy of a peptide boronic acid-serine protease complex in the crystalline state.

Farr-Jones S, Smith SO, Kettner CA, Griffin RG, Bachovchin WW.

Proc Natl Acad Sci U S A. 1989 Sep;86(18):6922-4.

22.

Crystal versus solution structures of enzymes: NMR spectroscopy of a crystalline serine protease.

Smith SO, Farr-Jones S, Griffin RG, Bachovchin WW.

Science. 1989 May 26;244(4907):961-4.

PMID:
2499045
23.

Nitrogen-15 NMR spectroscopy of the catalytic-triad histidine of a serine protease in peptide boronic acid inhibitor complexes.

Bachovchin WW, Wong WY, Farr-Jones S, Shenvi AB, Kettner CA.

Biochemistry. 1988 Oct 4;27(20):7689-97.

PMID:
3207700

Supplemental Content

Loading ...
Support Center